Vivlion, which also holds a license to Goethe University Frankfurt's CRISPR technology, will use the license to offer R&D reagents and screening services.
Researchers are hoping to make the technology a success for the environment and human health while avoiding the biases that resulted from the debate over GMOs.
The company will use the funding to expand its gene editing systems for potential therapeutic use, and to advance research and validation for its pipeline.
A US advisory committee says healthcare workers and nursing home residents should be prioritized to receive a SARS-CoV-2 vaccine, according to the Financial Times.
